Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy.

Morse GD, Catanzaro LM, Acosta EP.

Lancet Infect Dis. 2006 Apr;6(4):215-25. Review.

PMID:
16554246
2.

Protease inhibitor plasma concentrations in HIV antiretroviral therapy.

Justesen US.

Dan Med Bull. 2008 Nov;55(4):165-85. Review.

PMID:
19232158
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).

Pellegrin I, Wittkop L, Joubert LM, Neau D, Bollens D, Bonarek M, Girard PM, Fleury H, Winters B, Saux MC, Pellegrin JL, Thiébaut R, Breilh D; ANRS Co3 Aquitaine Cohort.

Antivir Ther. 2008;13(2):271-9.

PMID:
18505178
5.
6.

Predictors of virologic response to ritonavir-boosted protease inhibitors.

Marcelin AG, Flandre P, Peytavin G, Calvez V.

AIDS Rev. 2005 Oct-Dec;7(4):225-32. Review.

PMID:
16425962
7.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
8.

Therapeutic drug monitoring in HIV infection: current status and future directions.

Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber A, Merry C, Perno CF.

AIDS. 2002 Mar;16 Suppl 1:S5-37. Review.

PMID:
12035820
9.

The 2nd International Workshop on Clinical Pharmacology of HIV Therapy. April 2nd-4th 2001, Noordwijk, The Netherlands.

Kakuda TN, Williams LA, Hsu AF.

Expert Opin Pharmacother. 2001 Aug;2(8):1339-45.

PMID:
11585002
10.
12.

Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?

Ribera E, López-Cortés LF, Soriano V, Casado JL, Mallolas J.

Enferm Infecc Microbiol Clin. 2005 Jul;23 Suppl 2:41-67. Review. English, Spanish.

PMID:
16373004
14.

Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice.

Romano L, Venturi G, Giomi S, Pippi L, Valensin PE, Zazzi M.

J Med Virol. 2002 Feb;66(2):143-50.

PMID:
11782921
15.

Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.

Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, Respess R, Hertogs K, Larder B, Ochola D, Mermin J, Samb B, Lackritz E.

AIDS. 2003 Jul;17 Suppl 3:S39-48.

PMID:
14565608
16.

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.

Cleijsen RM, van de Ende ME, Kroon FP, Lunel FV, Koopmans PP, Gras L, de Wolf F, Burger DM.

J Antimicrob Chemother. 2007 Oct;60(4):897-900. Epub 2007 Aug 17.

PMID:
17704117
17.
18.
19.

The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.

J Clin Virol. 2007 Feb;38(2):131-8. Epub 2007 Jan 4.

PMID:
17208042
20.

Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.

Puig T, Pérez-Olmeda M, Rubio A, Ruiz L, Briones C, Franco JM, Gómez-Cano M, Stuyver L, Zamora L, Alvarez C, Leal M, Clotet B, Soriano V.

AIDS. 2000 Apr 14;14(6):727-32.

PMID:
10807196

Supplemental Content

Support Center